The 50% hemolysis rate assessment is a highly sensitive quantitative bioassay that determines the exact serum dilution, dose, or contact condition under which half of a standardized population of antibody-sensitized erythrocytes undergoes complement-mediated lysis. Performed by accredited third-party laboratories in accordance with frameworks such as ISO 10993-4, ASTM F756, and GB/T 16886.4, this technique underpins hemocompatibility evaluation of medical devices, functional complement testing, and quality control of biological products. This article explains the scientific principles, sample requirements, testing methods, calculation approaches, and typical applications of half-hemolysis endpoint assessment.
Technical Overview
The 50% hemolysis rate assessment is a classical immunohematological bioassay designed to identify the precise dilution or dose of complement-containing serum that lyses exactly one half of a standardized suspension of antibody-sensitized erythrocytes. In clinical immunology and laboratory medicine, this endpoint is universally recognized as the CH50 assay, or 50% complement hemolytic activity test. In the field of medical device evaluation, closely related half-lysis and hemolysis rate endpoints support hemocompatibility testing performed under ISO 10993-4 and its Chinese counterpart GB/T 16886.4.
The analytical principle is based on the ability of the complement system, a cascade of more than thirty heat-labile serum proteins, to form membrane attack complexes on antibody-coated erythrocytes. The resulting colloid-osmotic lysis releases intracellular hemoglobin into the surrounding medium, where it can be quantified by spectrophotometry at 540 to 545 nm. As increasing amounts of complement are added to a fixed number of sensitized cells, the resulting plot of percentage lysis versus complement concentration follows a sigmoidal curve. The steepest and most reproducible region of this curve lies at the midpoint, which is why 50% lysis is selected as the endpoint of maximum analytical sensitivity.
The sigmoidal relationship is linearized using the von Krogh equation, expressed in logarithmic form as log x = log K + (1/n) × log[y/(1-y)], where x is the relative amount of complement, y is the fraction of cells lysed, and n is an empirical constant. At 50% lysis, the term y/(1-y) equals one and its logarithm becomes zero, meaning that K directly represents the quantity of complement producing the half-lysis endpoint. The CH50 value is conventionally reported as the reciprocal of the serum dilution achieving 50% hemolysis under standardized conditions, typically expressed in units per milliliter (U/mL).
Several recognized standards and reference frameworks govern or inform this testing portfolio:
- ISO 10993-4, Biological evaluation of medical devices - Part 4: Selection of tests for interactions with blood
- ASTM F756, Standard Practice for Assessment of Hemolytic Properties of Materials
- ASTM F1984 and ASTM F2065 for complement activation testing of materials
- GB/T 16886.4 and GB/T 14233.2, Chinese national standards for hemolysis and biological test methods
- Classical Mayer methodology for titration of complement activity
Testing Samples
Serum Samples
Serum is the preferred matrix for functional complement assessment. Blood is collected into plain tubes, allowed to clot, and centrifuged to separate the serum, which is then stored frozen at -70°C or below and shipped on dry ice. Because complement proteins are thermally labile, repeated freeze-thaw cycles, prolonged room-temperature handling, and heat exposure must be strictly avoided to prevent artificial loss of activity.
Fresh Whole Blood
For material and device hemolysis testing, freshly drawn rabbit or human blood anticoagulated with sodium citrate, acid-citrate-dextrose (ACD), or heparin is used. EDTA is generally avoided for functional assays because it chelates calcium ions and irreversibly blocks the classical complement pathway. Blood should be tested promptly after collection to preserve erythrocyte integrity.
Medical Device Samples and Extracts
Blood-contacting devices such as catheters, stents, oxygenators, dialyzers, and infusion sets can be evaluated either by direct contact with whole blood or by testing aqueous extracts prepared according to ISO 10993-12. Standard extraction conditions include 37°C for 24 or 72 hours, 50°C for 72 hours, or 70°C for 24 hours, with extraction ratios based on surface area, thickness, or mass of the test article.
Biopharmaceutical Products
Immunoglobulin preparations, vaccines, blood substitutes, liposomal formulations, and nanoparticle-based drug products are frequently screened for hemolytic and complement-activating potential, since infusion-related reactions are often mediated by complement activation.
Testing Items
Typical testing items offered within a half-hemolysis assessment portfolio include the following:
- Total classical pathway hemolytic complement activity (CH50, U/mL)
- Alternative pathway hemolytic activity (AH50/AP50) using unsensitized rabbit erythrocytes in magnesium-EGTA buffer
- Direct-contact hemolysis rate of biomaterials and device cut sections
- Indirect (extract-based) hemolysis rate of devices and materials
- Half-hemolytic concentration or 50% hemolytic dose of soluble test articles
- Verification of positive and negative controls supporting assay validity
Testing Methods
Preparation of Sensitized Erythrocytes
Sheep erythrocytes are washed in buffered saline and standardized to a defined cell concentration. The cells are then sensitized with an optimally diluted rabbit anti-sheep erythrocyte antiserum (hemolysin or amboceptor) and incubated at 37°C, followed by washing to remove unbound antibody. Correct optimization of the hemolysin dilution is critical, as under- or over-sensitization shifts the assay away from the proportionality region required for accurate endpoint determination.
Classical CH50 Procedure
Serial dilutions of test serum are prepared in veronal-buffered saline containing calcium and magnesium ions. Equal volumes of diluted serum and sensitized sheep cells are mixed and incubated at 37°C for a defined period, typically 30 to 60 minutes. Following centrifugation, the absorbance of each supernatant is measured at approximately 541 nm. A reagent blank (cells in buffer only) defines 0% lysis, and complete lysis induced by distilled water or ammonium chloride solution defines 100% lysis.
Alternative Pathway Variant
To selectively measure alternative pathway activity, unsensitized rabbit erythrocytes are incubated with serum dilutions in buffer containing magnesium and EGTA, which chelates calcium and thereby blocks the classical and lectin pathways while leaving the alternative pathway intact.
Medical Device Hemolysis Test
For direct contact testing, the test article is incubated with diluted whole blood at 37°C under gentle agitation. For the indirect method, the material extract is incubated with diluted blood. After incubation, samples are centrifuged and the absorbance of the supernatant is recorded. Distilled water serves as the positive hemolytic control, while physiological saline or an established reference material serves as the negative control.
Calculation and Acceptance Criteria
Percentage lysis is calculated as (A_sample - A_blank) / (A_100% - A_blank) × 100. Complement titration results are plotted according to the von Krogh linearization, and the CH50 is derived from the interpolated 50% endpoint. For device testing, the hemolysis rate is calculated as (A_test - A_negative) / (A_positive - A_negative) × 100. Consistent with ASTM F756 and GB/T 16886.4 practice, a hemolysis rate below 5% is generally regarded as non-hemolytic, whereas values at or above 5% indicate hemolytic potential requiring further evaluation.
Applications
Hemocompatibility of Blood-Contacting Devices
Half-hemolysis and hemolysis rate data form a core element of the blood-interaction test panel required for regulatory submissions of cardiovascular devices, extracorporeal circuits, transfusion and infusion equipment, and blood collection systems, supporting risk assessment under ISO 10993-1 and ISO 10993-4.
Quality Control of Biologicals
Complement-dependent hemolytic assays are used to verify the functional potency of antibody-containing products and to confirm that purification processes have removed undesirable hemolytic or complement-consuming impurities.
Complement Diagnostics and Research
CH50 measurement detects gross deficiencies of classical pathway components and monitors disease activity or therapeutic complement inhibition in autoimmune and inflammatory conditions. AH50 testing in parallel helps localize pathway-specific defects.
Preclinical Safety Screening
Nanomedicines, contrast agents, and polymeric drug carriers are screened for complement activation because half-lysis endpoint shifts can signal infusion reaction risk before clinical exposure.
FAQ
Why is 50% lysis used as the endpoint instead of complete lysis?
The complement titration curve is sigmoidal, and its steepest slope occurs at the midpoint. Near 50% lysis, a small change in complement concentration produces the largest measurable change in hemolysis, giving the endpoint its superior sensitivity, precision, and reproducibility compared with the plateaus near 0% or 100% lysis.
What is the difference between CH50 and AH50?
CH50 measures the classical pathway, requiring antibody-sensitized sheep erythrocytes and calcium-dependent activation. AH50 measures the alternative pathway using unsensitized rabbit erythrocytes in magnesium-EGTA buffer. Running both assays in parallel allows localization of a complement defect to a specific pathway.
What are typical reference values for CH50?
Reference intervals are laboratory- and method-dependent, but total classical pathway activity in healthy adult serum is commonly reported in the approximate range of 30 to 75 U/mL. Markedly reduced or absent activity suggests component deficiency, inactivation, or consumption.
How should samples for complement testing be transported?
Serum should be separated promptly and frozen at -70°C or below as soon as possible, then shipped on dry ice with temperature monitoring. Hemolyzed, heat-exposed, or repeatedly thawed specimens are unsuitable because they yield artificially low activity.
What hemolysis rate is acceptable for a medical device?
Per ASTM F756 and GB/T 16886.4 conventions, a hemolysis rate below 5% is generally considered acceptable and non-hemolytic. Results at or above 5% are regarded as indicative of hemolytic properties and typically trigger material reformulation or additional hemocompatibility testing.
Which controls are required to validate the assay?
Each run must include a 0% lysis blank, a 100% lysis positive control such as distilled water, and a negative control such as saline or a validated reference material. Parallel testing of a serum with known complement activity is recommended to confirm assay performance.
